August 2023 Shareholder Update
18 August 2023
The QBiotics August 2023 Shareholder Update is now available to view/download.
18 August 2023
The QBiotics August 2023 Shareholder Update is now available to view/download.
Thank you for your interest in our anticancer product tigilanol tiglate. We post details of our clinical trials on clinical trial registries, such as the Australian New Zealand Clinical Trials Registry (ANZCTR) at www.anzctr.org.au.
Please note:
We understand how truly difficult this time is for those affected by cancer, as cancer has touched the lives, either personally or through our loved ones, of many of us at QBiotics. Please be assured that we are one hundred percent committed to develop products as quickly as possible that effectively and safely address challenging conditions.
With warm regards, the QBiotics team.
Thank you for your interest in our veterinary programme.
Tigilanol tiglate, our lead oncology compound has now been commercialised as a veterinary oncology product, STELFONTA®*.
STELFONTA* is approved by the Food and Drug Administration (FDA), European Medicines Agency (EMA), Veterinary Medicines Directorate (VMD), Australian Pesticides and Veterinary Medicine (APVMA) and Swissmedic; making it the first pharmaceutical treatment available for non resectable, non-metastatic mast cell tumours. As STELFONTA is registered as a prescription product, your veterinarian will be able to decide the best treatment for your dog.
We appreciate how distressing a cancer diagnosis for your pet can be, and wish you and your dog the very best during this time.Warmly, the QBiotics team.
* This link will take you to a product site that contains information that may not comply with the Australian regulatory requirements.
At QBiotics we are proud to be a small part of an important movement driving advances in oncology. Our recently registered pharmaceutical to treat canine mast cell tumours, STELFONTA® (tigilanol tiglate), is backed by a rigorous clinical research programme that we are committed to continue, with the aim of improving the health of companion animals. We are excited to launch the QBiotics’ Research Grant, to support veterinary oncologists and those with a special interest in oncology to deepen our collective understanding of the potential to use STELFONTA to treat solid tumours.
Contact Dr Pamela Jones for details pamela.jones@qbiotics.com
For information about our privacy practices, please view our privacy policy. You can unsubscribe at any time by clicking the link in the footer of our emails. We use Mailchimp as our marketing platform. By clicking above to register, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.